| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000023629 |
| Receipt No. | R000027115 |
| Scientific Title | Baseline characteristics of patients with COPD (chronic bronchitis, emphysema) who require LABA and LAMA (both free and fixed combination) for maintenance therapy other than tiotropium+olodaterol fixed dose combination (Tio+Olo FDC) assessed in parallel with the PMS of Tio+Olo FDC Respimat, BI trial number 1237.34 |
| Date of disclosure of the study information | 2016/08/21 |
| Last modified on | 2020/08/24 (Ver. 15) |
| Basic information | ||
| Public title | Baseline characteristics of patients with COPD (chronic bronchitis, emphysema) who require LABA and LAMA (both free and fixed combination) for maintenance therapy other than tiotropium+olodaterol fixed dose combination (Tio+Olo FDC) assessed in parallel with the PMS of Tio+Olo FDC Respimat, BI trial number 1237.34 | |
| Acronym | Baseline characteristics of patients with COPD (chronic bronchitis, emphysema) who require LABA and LAMA (BI trial number 1237.48) | |
| Scientific Title | Baseline characteristics of patients with COPD (chronic bronchitis, emphysema) who require LABA and LAMA (both free and fixed combination) for maintenance therapy other than tiotropium+olodaterol fixed dose combination (Tio+Olo FDC) assessed in parallel with the PMS of Tio+Olo FDC Respimat, BI trial number 1237.34 | |
| Scientific Title:Acronym | Baseline characteristics of patients with COPD (chronic bronchitis, emphysema) who require LABA and LAMA (BI trial number 1237.48) | |
| Region |
|
|
| Condition | ||
| Condition | COPD(chronic bronchitis, emphysema) | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | This survey is designed to assess baseline characteristics and potential channelling in patients with COPD (chronic bronchitis, emphysema) who require both LABA and LAMA (both free and fixed combination) for maintenance therapy other than Tio+Olo FDC sequentially enrolled in the half of sites in which other LABA/LAMA FDC or free combination could be prescribed and could participate in the PMS, in parallel in order to allow the same physicians can prescribe LABA/LAMA FDCs or free combinations during the same period. |
| Basic objectives2 | Others |
| Basic objectives -Others | This survey is designed to assess baseline characteristics without the information regarding safety and effectiveness.
|
| Trial characteristics_1 | Others |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase IV |
| Assessment | |
| Primary outcomes | Demographics(Sex,date of birth ,height, weight, smoking history, reason of LAMA+LABA administration), COPD status, LAMA + LABA combination administration status, Medical history, Concomitant disease,Previous/concomitant therapies, Concomitant/ past medications, CAT, FVC and FEV1 |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients who are newly prescribed LABA + LAMA combination (both free and fixed combination) or who are switched to new LABA + LAMA combination from conventional LABA and LAMA combination.
Patients with informed consent (excepted in case of opt-out procedure) sequentially to be enrolled by the same physicians in the PMS sites. |
|||
| Key exclusion criteria | Patients who are prescribed Tio+Olo FDC, Patients who have already been registered in this study once (re-entry of patients is not allowed).
Patients who are participating in a clinical trial or registry. Patients who have a contraindication to Tio+Olo FDC defined in the package insert for Tio+Olo FDC. |
|||
| Target sample size | 500 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Nippon Boehringer Ingelheim Co.,LTD | ||||||
| Division name | TA Asthma & COPD, Primary Care Medicine, Medicine Division | ||||||
| Zip code | 1416017 | ||||||
| Address | 2-1-1 Osaki,Shinagawa-ku,Tokyo | ||||||
| TEL | 03-6417-2471 | ||||||
| shuhei.nakamura@boehringer-ingelheim.com | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Nippon Boehringer Ingelheim Co.,LTD | ||||||
| Division name | TA Asthma & COPD, Primary Care Medicine, Medicine Division | ||||||
| Zip code | 1416017 | ||||||
| Address | 2-1-1 Osaki,Shinagawa-ku,Tokyo | ||||||
| TEL | 03-6417-2471 | ||||||
| Homepage URL | |||||||
| shuhei.nakamura@boehringer-ingelheim.com | |||||||
| Sponsor | |
| Institute | Nippon Boehringer Ingelheim Co.,LTD |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Nippon Boehringer Ingelheim Co.,LTD |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Iryokenkoshigenkaihatsu kenkyujo |
| Address | NA |
| Tel | 03-5904-8534 |
| jdw06164@nifty.com | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | http://www.pieronline.jp/content/article/0289-8020/41040/281 |
| Publication of results | Published |
| Result | |||||||
| URL related to results and publications | http://www.pieronline.jp/content/article/0289-8020/41040/281 | ||||||
| Number of participants that the trial has enrolled | 474 | ||||||
| Results | Mild COPD was slightly higher in the BCS than in the PMS. The mean post dose percent FEV1 and FEV1 FVC were numerically slightly higher in the BCS than in the PMS. The proportion of comorbidities, benign prostatic hyperplasi and gastroesophageal reflux disease, was numerically higher and lower, respectively, in the BCS than in the PMS. The proportion of previously received respiratory medication was higher in the BCS than in the PMS. |
||||||
| Results date posted |
|
||||||
| Results Delayed | |||||||
| Results Delay Reason | |||||||
| Date of the first journal publication of results | |||||||
| Baseline Characteristics | Mild COPD was slightly higher in the BCSthan in the PMS. The mean postdose percent FEV1 and FEV1FVC were numerically slightly higher in the BCS than in the PMS. The proportion of comorbidities, benign prostatic hyperplasia and gastroesophageal reflux disease, was numerically higher and lower than in the PMS. The proportion of previously received respiratory medication was higher in the BCS than in the PMS. |
||||||
| Participant flow | Continuous survery, same physician in same hospital or clinics for registration. |
||||||
| Adverse events | NA |
||||||
| Outcome measures | NA |
||||||
| Plan to share IPD | |||||||
| IPD sharing Plan description | |||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | This survey is designed to assess the characteristics in patients with COPD. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000027115 |